Abstract:The Lambert-Eaton myasthenic syndrome (LEMS) is a disease of neuromuscular transmission in which autoantibodies against the P/Q-type voltage-gated calcium channel (VGCC) at the presynaptic nerve terminal play a major role in decreasing quantal release of acetylcholine (ACh), resulting in skeletal muscle weakness and autonomic symptoms. It is associated with cancer, particularly small-cell lung carcinoma (SCLC), in 50-60% of LEMS patients; the nerve terminal and carcinoma cells apparently share a common antigen (VGCC), suggesting an immunological cross-reactivity that may lead to the neurological abnormality. Non-tumor LEMS has a strong association with HLA-DR3-B8. In approximately 15% of LEMS patients, no anti-P/Q-type VGCC antibodies are found, suggesting recognition of other targets(s). The VGCC-associated protein synaptotagmin could be one candidate, because it acts as an exocytotic calcium receptor, is implicated in fast ACh release; its N-terminus is exposed extracellularly during exocytosis and it is expressed in SCLC. Antibodies against synaptotagmin-1 were detected in both anti-VGCC-positive and -negative LEMS patients (20%), and it can be immunogenic, allowing induction of an animal model of LEMS. Another candidate target is the M1-type presynaptic muscarinic ACh receptor (M1 mAChR), also expressed extracellularly on motor nerve terminals; it modulates cholinergic transmission, linking to P/Q-type VGCC. In our series of 25 LEMS patients with and without SCLC, anti-M1 mAChR antibodies were prevalent in both anti-VGCC-positive and -negative LEMS patients. Autonomic symptoms seemed more frequent in the latter; serum from one of them passively transferred LEMS-type electrophysiological defects to mice. As a compensatory mechanism, researchers in Oxford suggested a shift in the dependence of ACh release from the P/Q-type to other types of VGCC. We have also focused on G protein-coupled mAChRs and neurotrophins, which may affect both P/Q-type VGCC and clathrin-independent "kiss-and-run" synaptic vesicle recycling (fast-mode of endocytosis) via protein kinase C activation. We hypothesize that these signaling cascades help to compensate for the immune-mediated defects in calcium entry in LEMS, compensation that may frequently be restricted by the coincident anti-M1 mAChR antibodies in this disease.

Lambert-Eaton myasthenic syndrome as an autoimmune calcium channelopathy

Lambert-Eaton myasthenic syndrome: search for alternative autoimmune targets and possible compensatory mechanisms based on presynaptic calcium homeostasis

[Lambert-Eaton Myasthenic Syndrome]

Lambert-Eaton syndrome

Autoantibodies against M1 muscarinic acetylcholine receptor in myasthenic disorders

Autoimmune disorders of neuromuscular transmission

[Recent advance in research for myasthenia gravis, in relation to various antibodies affecting synaptic structure and function]

Pathogenic Mechanisms and Clinical Correlations in Autoimmune Myasthenic Syndromes

Gamma-aminobutyric-acid-B Receptor Antibodies in Limbic Encephalitis with Small Cell Lung Cancer

[A case of myasthenia gravis with coexistence of anti-acetylcholine receptor antibodies and anti-P/Q-type VGCC antibodies]

Pearls and pitfalls in the diagnosis and management of neuromuscular junction disorders

Presynaptic Disorders: Lambert-Eaton Myasthenic Syndrome and Botulism

Intrathecal injection of P/Q type voltage-gated calcium channel antibodies from paraneoplastic cerebellar degeneration cause ataxia in mice

Myasthenia and related disorders of the neuromuscular junction

Humoral immunity against glutamic acid decarboxylase and tyrosine phosphatase IA-2 in Lambert-Eaton myasthenic syndrome

Neuromyotonia

Autonomic dysfunction detected by skin sympathetic response in Lambert-Eaton myasthenic syndrome: a case report

Antibodies Against Low-Density Lipoprotein Receptor-Related Protein 4 Induce Myasthenia Gravis.

Lambert-Eaton Myasthenic Syndrome in a Patient with Small-Cell Lung Cancer: A Case Report.

Rectal cancer with solitary hepatic metastasis and Lambert-Eaton myasthenic syndrome

Therapy in myasthenia gravis and Lambert-Eaton myasthenic syndrome